13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02493049 (ClinicalTrials.gov) | August 2015 | 2/7/2015 | Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) | Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Domperidone | University of Calgary | Alberta Innovates Health Solutions | Completed | 18 Years | 60 Years | All | 17 | Phase 2 | Canada |
| 2 | NCT02308137 (ClinicalTrials.gov) | February 2015 | 2/12/2014 | Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) | Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS) | Multiple Sclerosis, Secondary Progressive | Drug: Domperidone | University of Calgary | Alberta Innovates Health Solutions | Completed | 18 Years | 60 Years | All | 64 | Phase 2 | Canada |